TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Evaluate the Efficacy and Safety of 10mg Alfuzosin in the Treatment of Chronic Prostatitis / Chronic Pelvic Pain Syndrome (CP/CPPS) in Recently-Diagnosed and/or Newly-Symptomatic Alpha-blocker Naïve Patients
Brief Summary: The purpose of this randomized clinical trial is to evaluate the efficacy and safety of the alpha adrenergic blocker Alfuzosin (Uroxatral) in men with relatively new onset of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). Alfuzosin is a once daily (10 mg capsule), FDA approved medication for an indication in benign prostatic hyperplasia (BPH). The effectiveness of alfuzosin in improving lower urinary tract symptoms in patients with BPH has been documented in a number of placebo-controlled studies. A number of small studies have also suggested that alfuzosin ameliorates CP/CPPS symptoms through a similar alpha-blockade mechanism. This study will enable further testing of this hypothesis


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Arm Label: Silodosin 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 4 mg | Arm Label: Silodosin 8 mg; Type: EXPERIMENTAL; Interventions: Drug: Silodosin 8 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Silodosin 8 mg; Assigned to Arm(s): Silodosin 8 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Silodosin 4 mg; Assigned to Arm(s): Silodosin 4 mg
D: Arm Label: Alfuzosin; Type: EXPERIMENTAL; Interventions: Drug: Alfuzosin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alfuzosin; Assigned to Arm(s): Alfuzosin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial Investigating the Effect of Different Exercise Forms on Depression
Brief Summary: During one year, 5-8% of the population will suffer from major depression. Some of the key symptoms are loss of interest in daily activities, loss of energy and sleeping disturbances. The financial consequences of this disease is estimated to be more than 30 million pounds per year in Great Britain and USA alone. There is an increasing interest in the effect exercise has on depression. Smaller studies indicate that exercise is a good treatment for depression. This study will be a large scale randomized trial and will hopefully bring important knowledge on the effects exercise has on depression.

We will compare the effect endurance training, weight-lifting exercise and a control group has on depressive symptoms after 4 months training, twice a week.


Options:
A: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A
B: Arm Label: ACT; Type: EXPERIMENTAL; Interventions: Other: Acceptance and Commitment Therapy (ACT) | Arm Label: WPI; Type: EXPERIMENTAL; Interventions: Other: workplace intervention (WPI) | Arm Label: ACT and WPI; Type: EXPERIMENTAL; Interventions: Other: Acceptance and Commitment Therapy (ACT), Other: workplace intervention (WPI) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Acceptance and Commitment Therapy (ACT); Assigned to Arm(s): ACT, ACT and WPI | Intervention Type: OTHER; Name: workplace intervention (WPI); Assigned to Arm(s): ACT and WPI, WPI
C: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
D: Arm Label: Tree Theme Method ® (TTM) intervention; Type: EXPERIMENTAL; Interventions: Other: Tree Theme Method ® (TTM) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tree Theme Method ® (TTM); Assigned to Arm(s): Tree Theme Method ® (TTM) intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Clinical Trial Investigating the Effect of Different Exercise Forms on Depression
Brief Summary: During one year, 5-8% of the population will suffer from major depression. Some of the key symptoms are loss of interest in daily activities, loss of energy and sleeping disturbances. The financial consequences of this disease is estimated to be more than 30 million pounds per year in Great Britain and USA alone. There is an increasing interest in the effect exercise has on depression. Smaller studies indicate that exercise is a good treatment for depression. This study will be a large scale randomized trial and will hopefully bring important knowledge on the effects exercise has on depression.

We will compare the effect endurance training, weight-lifting exercise and a control group has on depressive symptoms after 4 months training, twice a week.


Options:
A: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Training Program | Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Training Program; Assigned to Arm(s): 2
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss treatment, Behavioral: Health education counseling | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Weight loss treatment, Behavioral: Behavior therapy for depression | Intervention Type: BEHAVIORAL; Name: Weight loss treatment; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Behavior therapy for depression; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Health education counseling; Assigned to Arm(s): 1
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Sleep deprivation, Procedure: Light therapy, Procedure: Diurnal rhythms, Drug: duloxetine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Drug: duloxetine | Intervention Type: PROCEDURE; Name: Sleep deprivation; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Light therapy; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Diurnal rhythms; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): B | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): B
D: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Study of DOXIL/CAELYX (Doxorubicin HCL Liposome Injection) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
Brief Summary: The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.


Options:
A: Arm Label: VDR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: Revlimid (lenalidomide) | Arm Label: VDCR; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide, Drug: Revlimid (lenalidomide) | Arm Label: VDC; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Arm Label: VDC-mod; Type: EXPERIMENTAL; Interventions: Drug: VELCADE (bortezomib), Drug: dexamethasone, Drug: cyclophosphamide | Intervention Type: DRUG; Name: VELCADE (bortezomib); Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): VDC, VDC-mod, VDCR, VDR | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): VDC, VDC-mod, VDCR | Intervention Type: DRUG; Name: Revlimid (lenalidomide); Assigned to Arm(s): VDCR, VDR
B: Intervention Type: DRUG; Name: Velcade; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: bortezomib; Assigned to Arm(s): N/A
D: Arm Label: VELCADE (bortezomib) monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bortezomib (VELCADE) | Arm Label: DOXIL/CAELYX in combination with VELCADE (bortezomib); Type: EXPERIMENTAL; Interventions: Drug: Bortezomib (VELCADE), Drug: Doxorubicin hydrochloride (DOXIL/CAELYX) | Intervention Type: DRUG; Name: Bortezomib (VELCADE); Assigned to Arm(s): VELCADE (bortezomib) monotherapy | Intervention Type: DRUG; Name: Bortezomib (VELCADE); Assigned to Arm(s): DOXIL/CAELYX in combination with VELCADE (bortezomib) | Intervention Type: DRUG; Name: Doxorubicin hydrochloride (DOXIL/CAELYX); Assigned to Arm(s): DOXIL/CAELYX in combination with VELCADE (bortezomib)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Brief Summary: The purposes of this study are to assess similarities and differences in the efficacy (how well the drug works), safety, and side effects of olanzapine and aripiprazole in patients with schizophrenia, schizoaffective disorder, or schizophreniform disorder.


Options:
A: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Aripiprazole; Assigned to Arm(s): N/A
B: Arm Label: ALKS 9072; Type: EXPERIMENTAL; Interventions: Drug: ALKS 9072 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ALKS 9072; Assigned to Arm(s): ALKS 9072 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Intramuscular Olanzepine 10 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance
Brief Summary: Thalassemia major is a genetic disorder affecting hemoglobin synthesis, rendering individuals dependent upon lifelong blood transfusions. Consequently, iron overload occurs and patients have shortened life expectancy with the most common cause of death being heart failure. This trial tests whether the combination of traditional therapy (deferoxamine) with a newer drug (deferiprone) will prove more effective in removing cardiac iron than deferoxamine alone.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (DFP) and Deferoxamine (DFO) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Deferiprone (DFP) | Intervention Type: DRUG; Name: Deferiprone (DFP) and Deferoxamine (DFO); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Deferiprone (DFP); Assigned to Arm(s): 2
B: Arm Label: ICL670; Type: EXPERIMENTAL; Interventions: Drug: ICL670 | Arm Label: Deferoxamine; Type: ACTIVE_COMPARATOR; Interventions: Drug: deferoxamine | Intervention Type: DRUG; Name: ICL670; Assigned to Arm(s): ICL670 | Intervention Type: DRUG; Name: deferoxamine; Assigned to Arm(s): Deferoxamine
C: Arm Label: Deferiprone + Desferrioxamine; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1), Drug: Desferrioxamine | Arm Label: Deferiprone single agent; Type: EXPERIMENTAL; Interventions: Drug: Deferiprone (L1) | Arm Label: Desferrioxamine single agent; Type: ACTIVE_COMPARATOR; Interventions: Drug: Desferrioxamine | Intervention Type: DRUG; Name: Deferiprone (L1); Assigned to Arm(s): Deferiprone + Desferrioxamine, Deferiprone single agent | Intervention Type: DRUG; Name: Desferrioxamine; Assigned to Arm(s): Deferiprone + Desferrioxamine, Desferrioxamine single agent
D: Intervention Type: DRUG; Name: deferiprone; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I Trial of Immunotherapy With BHT-3009 Alone or Combined With Atorvastatin in Patients With Multiple Sclerosis
Brief Summary: This research study is being done to evaluate the safety of BHT-3009 alone and when combined with atorvastatin (Lipitor) in patients with multiple sclerosis (MS).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Interferon-beta-1a, Drug: Simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Interferon-beta-1a, Drug: Placebo | Intervention Type: DRUG; Name: Interferon-beta-1a; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: BIOLOGICAL; Name: BHT-3009-01; Assigned to Arm(s): N/A
C: Arm Label: interferon; Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon beta treatment to add-on atorvastatin treatment | Arm Label: untreated; Type: SHAM_COMPARATOR; Interventions: Drug: untreated to atorvastatin treatment | Intervention Type: DRUG; Name: interferon beta treatment to add-on atorvastatin treatment; Assigned to Arm(s): interferon | Intervention Type: DRUG; Name: untreated to atorvastatin treatment; Assigned to Arm(s): untreated
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: simvastatin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: simvastatin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)
Brief Summary: Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis is the most common type of small blood vessel inflammation in adults. ANCA-associated vasculitis includes Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA). Rituximab is a man-made antibody used to treat certain types of cancer. The purpose of this study is to determine the effectiveness of rituximab in treating patients with WG and MPA.

Study hypothesis: Rituximab is not inferior to conventional therapy in its ability to induce disease remission by Month 6.


Options:
A: Arm Label: azathioprine, standard; Type: ACTIVE_COMPARATOR; Interventions: Drug: azathioprine | Arm Label: azathioprine, longterm; Type: EXPERIMENTAL; Interventions: Drug: azathioprine | Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): azathioprine, longterm, azathioprine, standard
B: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group), Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cyclophosphamide plus rituximab placebo (control group), Drug: Azathioprine, Drug: Methylprednisolone (or other glucocorticoid), Drug: Prednisone | Intervention Type: DRUG; Name: Rituximab plus cyclophosphamide placebo (rituximab group); Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Cyclophosphamide plus rituximab placebo (control group); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Methylprednisolone (or other glucocorticoid); Assigned to Arm(s): Control Group, Rituximab | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Control Group, Rituximab
C: Arm Label: Valaciclovir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Valaciclovir | Arm Label: No additional treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Valaciclovir; Assigned to Arm(s): Valaciclovir
D: Intervention Type: DRUG; Name: Azathioprine: 2 mg/kg/day; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: TOBI (tobramycin inhaled solution)/Placebo; Type: EXPERIMENTAL; Interventions: Drug: TOBI, Drug: Placebo | Arm Label: Placebo/TOBI; Type: PLACEBO_COMPARATOR; Interventions: Drug: TOBI, Drug: Placebo | Intervention Type: DRUG; Name: TOBI; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/TOBI, TOBI (tobramycin inhaled solution)/Placebo
C: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial With Aztreonam Lysinate for Inhalation in Cystic Fibrosis Patients With Pulmonary P. Aeruginosa Requiring Frequent Antibiotics (AIR-CF2)
Brief Summary: The purpose of this study was to evaluate the safety and efficacy of aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF) and lung infection due to Pseudomonas aeruginosa (PA).


Options:
A: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 150 mg Ivacaftor q12h; Type: EXPERIMENTAL; Interventions: Drug: Ivacaftor | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): 150 mg Ivacaftor q12h | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Patients with CF; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Arm Label: Age-matched healthy controls; Type: N/A; Interventions: Diagnostic Test: Questionnaire Patient Reported Outcome Measure (PROM) | Intervention Type: DIAGNOSTIC_TEST; Name: Questionnaire Patient Reported Outcome Measure (PROM); Assigned to Arm(s): Age-matched healthy controls, Patients with CF
D: Arm Label: Alginate oligosaccharide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Alginate oligosaccharide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alginate oligosaccharide; Assigned to Arm(s): Alginate oligosaccharide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A